Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

FDA published a final version of its guidance document, “Communications From Firms to Health Care Providers Regarding ...

Be cautious with your favorite pastries this week.

Public health experts worry the FDA workforce will be slashed, impeding the ability of the agency to review new medicines ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...